乌司他丁联合注射用亚胺培南西司他丁钠治疗重症肺炎伴呼吸衰竭的临床效果

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (497 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore clinical effect and safety of Ulinastatin combined with Imipenem and Cilastatin Sodium for Injection in the treatment of severe pneumonia with respiratory failure. Methods Eighty cases of severe pneumonia patients with respiratory failure admitted to Jinzhou Central Hospital from January 2014 to May 2019 were selected and divided into the control group (40 cases) and the observasion group (40 cases) according to random number table method. The control group was treated with Imipenem and Cilastatin Sodium for Injection, and the observation group was treated with Ulinastatin combined with Imipenem and Cilastatin Sodium for Injection. The two groups were treated for 10 days. Clinical effect was evaluated after treatment. The forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), peak expiratory flow (PEF), arterial partial pressure of oxygen (PaO2), arterial partial pressure of carbon dioxide (PaCO2), oxygenation index (OI), serum procalcitonin (PCT), C-reactive protein (CRP), interleukin-6 (IL-6) of the two groups were compared. The adverse reactions of the two groups during the treatment were recorded and compared. Results The total effective rate of the observation group was significantly higher than that of the control group (P ＜ 0.05). After treatment, the FEV1, FVC, PEF, PaO2, OI of the two groups were significantly higher than those before treatment (P ＜ 0.05), and PaCO2 was significantly lower than those before treatment (P ＜ 0.05), while FEV1, FVC, PEF, PaO2 and OI in the observation group were significantly higher than those in the control group (P ＜ 0.05), and PaCO2 was significantly lower than that in the control group (P ＜ 0.05). The levels of serum PCT, CRP and IL-6 in the two groups after treatment were significantly lower than those before treatment (P ＜ 0.05), and the levels of serum PCT, CRP and IL-6 in the observation group after treatment were significantly lower than those in the control group (P ＜ 0.05). During treatment, there was no adverse reaction in the two groups. Conclusion Ulinastatin combined with Imipenem and Cilastatin Sodium for Injection in the treatment of severe pneumonia with respiratory failure has a significant effect, which can improve the lung function and blood gas indexes, reduce the serum levels of inflammatory factors, and has good safety.

Key words： Severe pneumonia Respiratory failure Ulinastatin Imipenem and Cilastatin Sodium for Injection Effect Safety

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	FENG Xianrong1 WU Nan1 NIU Weiwei2

Cite this article:

FENG Xianrong1 WU Nan1 NIU Weiwei2. Clinical effect of Ulinastatin combined with Imipenem and Cilastatin Sodium for Injection in the treatment of severe pneumonia with respiratory failure[J]. 中国医药导报, 2020, 17(3): 123-126.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I3/123

[1] 何丰华，刘毓姿，吴晔，等.麻杏石甘汤治疗痰热壅肺型重症肺炎的临床研究[J].国际中医中药杂志，2015，37（3）：220-223.
[2] 于淼.无创呼吸机在重症肺炎伴发呼吸衰竭治疗上的效果评价[J].中国医疗器械信息，2018，24（17）：116，145.
[3] 鄢楠.不同治疗方法应用于重症肺炎伴呼吸衰竭患者的治疗效果分析[J].医学理论与实践，2018，31（11）：1610-1611.
[4] 胡金科，谭康新.亚胺培南西司他丁钠和头孢哌酮舒巴坦治疗重症肺炎的对比[J].实用中西医结合临床，2019， 19（6）：120-122.
[5] 赵欣黔，武卉，罗恩，等.注射用乌司他丁治疗婴幼儿重症肺炎临床疗效观察[J].中国现代医学杂志，2014，24（19）：100-101.
[6] Mandell LA，Wunderink RG，Anzueto A，et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults [J]. Clin Infect Dis，2007， 44 Suppl 2：S27-S72.
[7] 张秀敏，武海燕，孙晓娟.ICU无创呼吸机对COPD合并Ⅱ型呼吸衰竭的疗效观察[J].海南医学院学报，2016，22（14）：1499-1501.
[8] 石小羊.中西医结合治疗重症肺炎呼吸衰竭临床疗效分析[J].内蒙古中医药，2017，36（6）：79.
[9] 张衡，关动，院江丽，等.亚胺培南-西司他丁钠与阿奇霉素联用对重症肺炎患儿的临床疗效与安全性评价[J].抗感染药学，2019，16（2）：245-247.
[10] 黄崇敏.亚胺培南西司他丁钠治疗重症肺炎疗效观察[J].海峡药学，2018，30（9）：200-201.
[11] 高莹，李丽，张云.乌司他丁可降低重症肺炎患者的血清炎性因子水平并改善肺功能[J].基因组学与应用生物学，2019，38（2）：907-910.
[12] 高飞，尹纪来，王永存.乌司他丁联合奥曲肽对急性重症胰腺炎患者的临床研究[J].中国临床药理学杂志，2019， 35（18）：2013-2015.
[13] 蔡长勇，岑坚兴，郑浪宁.丹红注射液联合无创呼吸机辅助呼吸在重症肺炎致呼吸衰竭抢救中的应用价值[J].海南医学，2019，30（12）：1510-1512.
[14] 陈勇，李星，邱世明，等.亚胺培南西司他丁联合乌司他丁对重症肺炎并呼吸衰竭患者呼吸功能、血清炎性因子水平的影响[J].实用心脑肺血管病杂志，2018，26（5）：125-127.
[15] 王书英，刘磊.乌司他丁对重症肺炎患者呼吸功能及炎性应激状态的影响[J].实用临床医药杂志，2016，20（7）：34-37.
[16] 覃勇民，韦庆，唐毓宜，等.不同严重程度肺炎患者血清D-D、CRP、PCT水平比较[J].检验医学与临床，2019，16（14）：2051-2054.
[17] 董双霞，潘林艳，金海珍.重症肺炎中超敏C反应蛋白及D-二聚体早期诊疗价值及预后影响因素分析[J].中国药物与临床，2019，19（12）：2035-2037.
[18] 韩利，张筠，张铁栓.重症肺炎患者D-二聚体、纤维蛋白原、IL-6水平变化及其临床意义[J].中国呼吸与危重监护杂志，2017，16（1）：71-73.
[19] 赵秀清，陈伟.乌司他丁联合亚胺培南西司他丁钠治疗老年重症肺炎的效果评价[J].当代医药论丛，2018，16（8）：81-83.
[20] 杜海莲，喻俊峰.亚胺培南西司他丁钠联合头孢哌酮钠舒巴坦钠治疗重症肺部感染的临床效果观察[J].临床合理用药杂志，2019，12（20）：50-51.